Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Common Equity: 2010-2024

Historic Common Equity for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to -$135.4 million.

  • Cytokinetics' Common Equity fell 3646.12% to -$521.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$521.1 million, marking a year-over-year decrease of 3646.12%. This contributed to the annual value of -$135.4 million for FY2024, which is 64.96% up from last year.
  • Cytokinetics' Common Equity amounted to -$135.4 million in FY2024, which was up 64.96% from -$386.3 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Common Equity registered a high of $243.9 million during FY2021, and its lowest value of -$386.3 million during FY2023.
  • Its 3-year average for Common Equity is -$209.9 million, with a median of -$135.4 million in 2024.
  • In the last 5 years, Cytokinetics' Common Equity soared by 1,136.69% in 2020 and then tumbled by 258.04% in 2023.
  • Cytokinetics' Common Equity (Yearly) stood at $113.4 million in 2020, then surged by 115.08% to $243.9 million in 2021, then tumbled by 144.25% to -$107.9 million in 2022, then tumbled by 258.04% to -$386.3 million in 2023, then surged by 64.96% to -$135.4 million in 2024.